 Lille, France; Cambridge , M A ; April 2 2 , 202 1 - GENFIT Nasdaq and Euronext: GNFT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that Thomas Baetz has been appointed as Chief Financial Officer. Thomas Baetz joins the Executive Committee, along with Stefanie Magner, Chief Compliance Officer. 